Phase 1-2 trial evaluating anti-TGFβ agent (SAR439459) or pomalidomide in combination with isatuximab and dexamethasone in relapsed or refractory multiple myeloma (RRMM)

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date24/02/21 → 31/12/26
View all
View less

Keywords

  • Malignant Haematology
  • Multiple myeloma
  • Clinical trial